ZVRA (Zevra Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 25, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-05-25), Zevra Therapeutics's share price is $8.65. Zevra Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.29. Hence, Zevra Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Zevra Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 12 years, Zevra Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 82.03. The lowest was 11.26. And the median was 18.40.

ZVRA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.645
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Zevra Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.15. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.29.

During the past 12 years, Zevra Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 76.20% per year. The lowest was -54.50% per year. And the median was -3.20% per year.

Zevra Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Zevra Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Price-to-Operating-Cash-Flow Chart

Zevra Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

24.81

Zevra Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Zevra Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Zevra Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Zevra Therapeutics Price-to-Operating-Cash-Flow Calculation

Zevra Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	8.65	/	-1.291
	=

Zevra Therapeutics's Share Price of today is $8.65.
Zevra Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.29.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Zevra Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

1GDA:Germany 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Executives

Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241